Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1358894 in post-traumatic stress disorder
2021-003154-23Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing BI 1358894 with Placebo (2 arms). Primary endpoint: Change from baseline in CAPS-5 total severity score at Week 8. Started Nov 2021; status: completed.
02
Drugs
bi 1358894
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on 2021-003154-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003154-23.